Monopar study shows ALXN1840 improves copper balance in Wilson disease

May 19, 2026 5:33 PM

Monopar Therapeutics Inc. (NASDAQ: MNPR) announced that Hepatology Communications published results from a Phase 2 study of ALXN1840 (tiomolibdate choline) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found